New PET scan agent could spot kidney cancer more accurately
NCT ID NCT06680089
First seen Jan 07, 2026 · Last updated Jun 21, 2026 · Updated 31 times
Summary
This study tests a new radioactive imaging agent called [18F]RCCB6 for PET/CT scans to see if it can better detect kidney cancer, especially the most common type, clear cell renal cell carcinoma. Researchers will enroll 300 adults with confirmed or suspected kidney cancer. The goal is to see how the agent spreads in the body and how well it identifies tumors compared to standard scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
RECRUITINGShanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[18F]RCCB6 (a radioactive imaging agent)
What this could lead to
If successful, this could provide a more accurate, non-invasive way to detect and monitor kidney cancer, potentially reducing the need for biopsies.
What could go wrong
This is a phase 2 trial with 300 participants, so it is still early. The imaging agent may not prove significantly better than existing methods, and its availability may be limited.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.